Zynerba Pharmaceuticals, Inc. ZYNE · Stock Open Zynerba Pharmaceuticals, Inc. in new tab
Zynerba Pharmaceuticals, Inc. Analysis (ZYNE)
Is Zynerba Pharmaceuticals, Inc. a good investment? Zynerba Pharmaceuticals, Inc. (ZYNE) is currently trading at 1.30 USD.
Investor FAQ
Does Zynerba Pharmaceuticals, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Zynerba Pharmaceuticals, Inc.?
Zynerba Pharmaceuticals, Inc. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.
Company Profile
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.
Community Discussion